drugs now also have analyzed their samples using aSyn-SAA , including biotech company Biogen , for its alpha-synuclein immunotherapy trial .
Exploring Overlapping Pathologies in Neurodegenerative Diseases
For decades , researchers suspected they could find clues to the puzzle of why Parkinson ’ s clinically manifests differently from person to person in the biology that underpins PD , including the possibility of overlaps with Alzheimer ’ s disease that cause some people to experience more cognitive impairments .
The new biomarker is now providing revelatory insights into the continuum of biological dysfunctions that give rise to Parkinson ’ s , Alzheimer ’ s and other forms of dementia . Earlier
10